22:11 , Nov 7, 2018 |  BC Innovations  |  Translation in Brief

M is for Chemoproteomic Momentum

An October Nature paper from a University of Cambridge team is the second in as many years to highlight the utility of functionalizing methionine, an amino acid that has garnered less attention than others in...
16:02 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting MGLL could help treat chemotherapy-induced neuropathic pain. In a mouse model of paclitaxel-induced neuropathic pain, two tool compound MGLL inhibitors decreased mechanical allodynia compared with vehicle. Next steps could...
15:17 , Mar 30, 2018 |  BC Week In Review  |  Company News

Celgene licenses preclinical candidate from Abide

Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to preclinical candidate ABX-1772 from Abide Therapeutics Inc. (San Diego, Calif.), and the companies terminated a 2014 deal under which Celgene had rights to ABX-1431, an option to...
22:21 , Mar 28, 2018 |  BC Extra  |  Company News

Celgene, Abide reshuffle partnership

Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to preclinical candidate ABX-1772 from Abide Therapeutics Inc. (San Diego, Calif.), and the companies terminated a 2014 deal under which Celgene had rights to ABX-1431, an option to...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
04:00 , Oct 28, 2017 |  BioCentury  |  Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
00:31 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Abide begins Phase Ib trial for neuroinflammatory pain candidate ABX-1431

Abide Therapeutics Inc. (San Diego, Calif.) began a crossover Phase Ib trial of ABX-1431 to treat neuroinflammatory disorders associated with central pain. ABX-1431 is a small molecule inhibitor of monoglyceride lipase (MGLL; MAGL), which regulates...
01:35 , Aug 11, 2017 |  BC Innovations  |  Tools & Techniques

K follows C in chemoproteomics

A year after publishing a map of druggable cysteines in the proteome, Ben Cravatt’s lab at Scripps has reported its chemoproteomics tools can also profile lysines. By identifying reactive lysines in dozens of proteins for...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Abide Therapeutics, Celgene deal

Celgene exercised an option from a 2014 deal and will obtain worldwide rights outside the U.S. to Abide’s ABX-1431 . The product is in Phase Ia testing, and Abide plans to conduct additional Phase Ib...
07:00 , Sep 29, 2016 |  BC Extra  |  Company News

Celgene opts in for ex-U.S. rights to Abide compound

Celgene Corp. (NASDAQ:CELG) exercised an option giving it ex-U.S. rights to ABX-1431 from Abide Therapeutics Inc. (San Diego, Calif.). The small molecule inhibitor of monoacylglycerol lipase ( MAGL ) is in Phase I testing for...